Search hospitals > Iowa > Des Moines
Mission Cancer and Blood - Laurel
Claim this profileDes Moines, Iowa 50314
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Adenocarcinoma
Conducts research for Recurrence
Conducts research for Lung Cancer
172 reported clinical trials
1 medical researcher
Summary
Mission Cancer and Blood - Laurel is a medical facility located in Des Moines, Iowa. This center is recognized for care of Cancer, Breast Cancer, Adenocarcinoma, Recurrence, Lung Cancer and other specialties. Mission Cancer and Blood - Laurel is involved with conducting 172 clinical trials across 330 conditions. There are 1 research doctors associated with this hospital, such as Richard L. Deming.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
ER positive
HER2 negative
Top PIs
Clinical Trials running at Mission Cancer and Blood - Laurel
Breast Cancer
Lung Cancer
Cancer
Non-Small Cell Lung Cancer
Bladder Cancer
Squamous Cell Carcinoma
Bladder Carcinoma
Colorectal Cancer
Renal Cell Carcinoma
Pancreatic Cancer
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Radiation and HER2-Targeted Therapy
for Breast Cancer
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Recruiting2 awards Phase 315 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Mission Cancer and Blood - Laurel?
Mission Cancer and Blood - Laurel is a medical facility located in Des Moines, Iowa. This center is recognized for care of Cancer, Breast Cancer, Adenocarcinoma, Recurrence, Lung Cancer and other specialties. Mission Cancer and Blood - Laurel is involved with conducting 172 clinical trials across 330 conditions. There are 1 research doctors associated with this hospital, such as Richard L. Deming.